Rayos (Prednisone) Patent Expiration, LOE Window & CMS Spending

Rayos (Prednisone) by Amgen: FDA Orange Book LOE 2028-01-07, 21 AB generics, $19.1M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAmgen
FDA Application & PathwayN202020 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2028-01-07
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors21
2024 CMS Total Public Spend$19.1M
2024 Medicare Part D Spend$16.1M
2024 Medicaid Spend$3.0M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Amgen across sibling Meru public-data platforms.